Cambridge, MA, May 5, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials. The content provides scientific data in a consumable manner, summarizing the...
Category: News
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first...
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
Cambridge, MA, May 5, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on May 10, 2021 (the “Expiration Date”). Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are...
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5 million stock and warrant issuance to a subsidiary of Innoviva Inc. (Nasdaq: INVA) (“Innoviva”),...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, May 03, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 15,000 ordinary shares of Nabriva Therapeutics as an inducement to two...
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non-albicans Candida VVC and/or severe...
Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on...
Melinta Therapeutics and Hikma sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region
MORRISTOWN, N.J. – April 29, 2021 – Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere®(meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region. In the United States, Orbactiv® is indicated for the...
Summit Therapeutics Announces Commencement of Rights Offering
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to 14,312,977 shares of the Company’s common stock, par value $0.01 (the “Shares,” and each, a “Share”) based on...
Summit Therapeutics Announces Commencement of Rights Offering
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to 14,312,977 shares of the Company’s common stock, par value $0.01 (the “Shares,” and each, a “Share”) based on...